last year, while gross profit margin was slightly strengthened from 6.83% in 1H/2016 to 7.89% in 1H/2017. Other income in 1H/2017 amounted to Baht 741.35 million, a surge by Baht 375.49 million or 102.63
, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th 2. Costs of sales and gross profit Costs of sales were Baht 117 .60 million in the first nine months of 2019, a surge of Baht 32 .42 million
related corporate tax transaction, the normalized net profit would be approximately THB 97.42 million or a surge of 48% yoy. Page 3 of 4 Statement of Financial Position as of March 31, 2019 The consolidated
March 2018 increased by 19% yoy mainly from the surge of provisions for employee benefit and other liabilities. Most of the increase of other liabilities was income tax payable on 2017 profit because
% 51.41 63.64% 4. Livestock 11.47 3.62% 9.27 2.50% (2.20) (19.18%) Total Sales revenues 316.83 100.00% 371.33 100.00% 54.50 17.20% Such growth was driven by a surge in revenues from sales of companion
www.interpharma.co.th Inter Pharma Co. Ltd. 140/9 ITF Tower, 9th Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th a surge in revenues from sales of
administrative expenses for the three months period ended 31 March 2018 and 2019 at THB 34.11 million and THB 40.14 million respectively. This equals to a surge of 17.68 % in administrative expenses year on year
& expenses (net of tax) from the comparing quarters, the normalized net profit would be approximately THB 72.8 million in 2Q19 comparing to THB 52.4 million in 2Q18 or a surge of 39% . Statement of Financial
. Tambon Tarsit, Amohoe Pluag-daeng, Rayong As of June 30, 2018 the Company and its subsidiary had a significant surge in trade and other receivables when compared to last year which was mainly from an